Browse our anti-APOC1 (APOC1) Antibodies

Full name:
anti-Apolipoprotein C-I Antibodies (APOC1)
On are 133 Apolipoprotein C-I (APOC1) Antibodies from 17 different suppliers available. Additionally we are shipping APOC1 Kits (58) and APOC1 Proteins (27) and many more products for this protein. A total of 222 APOC1 products are currently listed.
ALPCI, Apo-CIB, ApoC-IB, apoc1, LRRG04
list all antibodies Gene Name GeneID UniProt
APOC1 341 P02654
APOC1 25292 P19939
APOC1 11812 P34928

Show all species

Show all synonyms

Most Popular Reactivities for anti-APOC1 (APOC1) Antibodies

Select your species and application

anti-Human APOC1 Antibodies:

anti-Rat (Rattus) APOC1 Antibodies:

anti-Mouse (Murine) APOC1 Antibodies:

All available anti-APOC1 Antibodies

Go to our pre-filtered search.

Top referenced anti-APOC1 Antibodies

  1. Human Monoclonal APOC1 Primary Antibody for ELISA, WB - ABIN559900 : Meunier, Russell, Engle, Faulk, Purcell, Emerson: Apolipoprotein c1 association with hepatitis C virus. in Journal of virology 2008 (PubMed)
    Show all 3 references for 559900

  2. Human Polyclonal APOC1 Primary Antibody for IHC (p), IP - ABIN152922 : Sun, Lin, Lee, Wang, Cheng, Wu, Chang, Lai, Shieh, Young: Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. in Gut 2013 (PubMed)

  3. Human Polyclonal APOC1 Primary Antibody for ELISA, IHC - ABIN4281201 : Berbée, van der Hoogt, Sundararaman, Havekes, Rensen: Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. in Journal of lipid research 2005 (PubMed)

More Antibodies against APOC1 Interaction Partners

Cow (Bovine) Apolipoprotein C-I (APOC1) interaction partners

  1. apoC-I and apoC-III (show APOC3 Antibodies) inhibit lipolysis by displacing LPL (show LPL Antibodies) from lipid emulsion particles. We also propose a role for these apolipoproteins in the irreversible inactivation of LPL (show LPL Antibodies) by factors such as angptl4 (show ANGPTL4 Antibodies).

Human Apolipoprotein C-I (APOC1) interaction partners

  1. APOC1 expression induces glomerulosclerosis, potentially by increasing the cytokine response in macrophages.

  2. apoC-I inhibited in situ LPL (show LCP1 Antibodies) activity in adipocytes in both a concentration- and time-dependent manner. There was no change in postprandial WAT apoC-I secretion. WAT apoC-I secretion may inhibit WAT LPL (show LCP1 Antibodies) activity and promote delayed chylomicron clearance in overweight and obese subjects

  3. People with allelic variation in four genes related to cardiovascular diseases and metabolism were more likely to die: apolipoprotein (APO (show C9orf3 Antibodies))C1 GG and AG carriers, APOE (show APOE Antibodies) varepsilon4 carriers, insulin-degrading enzyme (IDE (show IDE Antibodies)) TC carriers, and phosphatidylinositol 3-kinase (PI3KCB) GG carriers.

  4. Common single-nucleotide polymorphism in the APOC1/APOE (show APOE Antibodies) region, previously found to be associated with protective levels of cholesterol and lower cardiovascular risk, may be associated with ideal health.

  5. These findings indicated that variants in TOMM40 (show TOMM40 Antibodies)/APOE (show APOE Antibodies)/APOC1 region might be associated with human longevity. Further studies are needed to identify the causal genetic variants influencing human longevity.

  6. These results suggest that ApoC-I peptides may be a potential diagnostic biomarker and therapeutic approach for breast cancer.

  7. APOC1 SNP is associated with the A beta (show SUCLA2 Antibodies)-42 levels in CSF (show CSF2 Antibodies).

  8. This sbioinformatics analysis explored the shared genetic etiology underlying Type 2 Diabetes and Alzheimer's Disease on SNP level, gene level, and pathway level. Six SNPs on APOC1 gene.

  9. The endogenous retroviral promoters (LTRs) of the human endothelin B receptor (EDNRB (show EDNRB Antibodies)) and apolipoprotein C1 (APOC1) genes have high sequence identity but differ in activity and tissue specificity.

  10. The ability of apoC1 to inhibit CETP (show CETP Antibodies) activity is impaired in patients with diabetes. Glycation of apoC1 leads to a change in its electrostatic properties that might account, at least in part, for a loss of constitutive CETP (show CETP Antibodies) inhibition and an increase in plasma CETP (show CETP Antibodies) activity in patients with diabetes.

Mouse (Murine) Apolipoprotein C-I (APOC1) interaction partners

  1. APOC1 expression induces glomerulosclerosis, potentially by increasing the cytokine response in macrophages.

  2. Apolipoprotein C-I was significantly increased in obese mice plasma.

  3. The absence of ApoC-I results in impaired memory functions, which is, together with previous data, suggestive of an important, bell-shaped gene-dose dependent role for ApoC-I in appropriate brain functioning

  4. Data show that the stimulating effect of apoCI on the lipopolysaccharide (LPS (show TLR4 Antibodies))response resembles that of LPS-binding protein (LBP (show LBP Antibodies)) and depends on CD14 (show CD14 Antibodies)/ Toll-like receptor 4 (show TLR4 Antibodies) signaling.

  5. present observations provide direct support for a potent specific inhibition of CETP (show CETP Antibodies) by plasma apoCI in vivo

  6. The apoC-I content of lipoprotein remnants may serve as an early marker of coronary artery disease risk.

  7. TR4 (show NR2C2 Antibodies) can also regulate apolipoprotein E (show APOE Antibodies), C-I, and C-II gene expression via the TR4 (show NR2C2 Antibodies) response element within the hepatic control region

  8. apoC-I is a potent inhibitor of LPL (show LPL Antibodies)-mediated triglyceride lipolysis

  9. irrespective of receptor-mediated remnant clearance by the liver, liver-specific expression of recombinant human apoCI causes hypertriglyceridemia in the absence of the VLDLr (show VLDLR Antibodies) and apoCIII (show APOC3 Antibodies) in mice

  10. Endogenous apoC-I increases hyperlipidemia in apoE (show APOE Antibodies)-knockout mice by stimulating VLDL production and inhibiting LPL (show LPL Antibodies).

Rabbit Apolipoprotein C-I (APOC1) interaction partners

  1. Cholesteryl ester transfer protein (show CETP Antibodies) is the sole major determinant of cholesteryl ester transfer in normolipidemic rabbit plasma as a result of the inability of rabbit apoCI to change HDL (show HSD11B1 Antibodies) electronegativity.

APOC1 Antigen Profile

Antigen Summary

The protein encoded by this gene is a member of the apolipoprotein C1 family. This gene is expressed primarily in the liver, and it is activated when monocytes differentiate into macrophages. A pseudogene of this gene is located 4 kb downstream in the same orientation, on the same chromosome. This gene is mapped to chromosome 19, where it resides within a apolipoprotein gene cluster. Alternatively spliced transcript variants have been found for this gene, but the biological validity of some variants has not been determined.

Alternative names and synonyms associated with APOC1

  • apolipoprotein C-I (APOC1) antibody
  • Apolipoprotein C-I (apoc1) antibody
  • apolipoprotein C-I (Apoc1) antibody
  • ALPCI antibody
  • Apo-CIB antibody
  • ApoC-IB antibody
  • apoc1 antibody
  • LRRG04 antibody

Protein level used designations for APOC1

apolipoprotein C-I , Apolipoprotein C-I , apo-CIB , apoC-IB , apolipoprotein C1 , apo-CI , apoC-I , liver regeneration-related protein LRRG04

281633 Bos taurus
743864 Pan troglodytes
743907 Pan troglodytes
100196333 Salmo salar
341 Homo sapiens
25292 Rattus norvegicus
11812 Mus musculus
100301528 Oryctolagus cuniculus
476437 Canis lupus familiaris
Selected quality suppliers for anti-APOC1 (APOC1) Antibodies
Did you look for something else?